About HizentraInitiating HizentraAssistance and SupportSHARE Nurse Training and ExamInfusion Support CenterManaging Common ReactionsInfusion EquipmentInfusion Support ToolsInfusion ChecklistProfessional ResourcesFrequently Asked QuestionsRequest More InformationImportant Safety Information

Patient skills checklist for self-administration of SCIg

It is important to be prepared to teach your patients how to properly self-administer Hizentra. Use this checklist to help you remember what skills to review with your patients. You can also print this checklist.

____________________________________________________
Patient Name (please print clearly)

Patient Skills ReviewedIntroduced RN Initials/DateReinforced RN Initials/DateMastered RN Initials/Date
1. Define subcutaneous administration   
2. Describe appropriate sites for SCIg catheter placement   
3. Describe appropriate care of subcutaneous infusion site   
4. Describe signs/symptoms of subcutaneous needle complications   
5. Identify appropriate interventions for complications   
6. Scenarios to be discussed:
  • Blood return in tubing upon pullback
  • Pump malfunction/alarms
  • Site reactions
  • Other adverse events: headache, rash
   
7. Gather appropriate supplies for proper administration and aseptic technique   
8. Demonstrate proficiency in setting up (priming) tubing   
9. Demonstrate proficiency in inserting subcutaneous catheter and checking for blood return   
10. Demonstrate proficiency in discontinuing subcutaneous infusion   
11. Demonstrate proficiency in filling syringe or cassette   
12. Demonstrate understanding of storage and disposal of biological waste   
13. Demonstrate understanding of postinfusion site care   
14. Demonstrate understanding of care and maintenance of infusion pump   
15. Demonstrate understanding of appropriate use of EpiPen®   
16. Additional patient-specific tasks (if applicable)   
 

EpiPen® is a registered trademark of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Dey Pharma, L.P.

Print a Patient Skills Checklist

Support for you and your patients

Find a variety of professional resources, useful links, and clinical publications about Hizentra.

View resources

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, is indicated as replacement therapy for patients with primary humoral immunodeficiency (PI), age 2 and older. This includes but is not limited to the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

Hizentra is contraindicated in patients with a history of anaphylactic or severe systemic reaction to human immune globulin preparations or components of Hizentra, such as polysorbate 80. Because it contains the stabilizer L-proline, Hizentra is contraindicated in patients with hyperprolinemia. Hizentra is also contraindicated in patients with immunoglobulin A deficiency who have antibodies against IgA and a history of hypersensitivity.

Hizentra should be administered subcutaneously only. Do not administer intravenously.

IgA-deficient patients with anti-IgA antibodies may be at greater risk of developing potentially severe hypersensitivity and anaphylactic reactions with administration of Hizentra. If hypersensitivity occurs or anaphylactic reactions are suspected, discontinue administration immediately and treat as medically appropriate.

Hizentra is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common drug-related adverse reactions (observed in 5% or more of study subjects receiving Hizentra) were local reactions (ie, swelling, redness, heat, pain, and itching at the injection site), headache, diarrhea, fatigue, back pain, nausea, extremity pain, cough, rash, pruritis, vomiting, upper abdominal pain, pain, and migraine.

Monitor patients for thrombotic events and aseptic meningitis (AMS), which have been reported with SCIg. Also look forreactions reported to occur with IVIg treatment that might also occur with Hizentra, including renal dysfunction/failure, hemolysis, and transfusion-related acute lung injury (TRALI).

Ig administration can transiently impair the efficacy of live attenuated virus vaccines, such as measles, mumps and rubella. It can also lead to misinterpretation of serologic testing.

Please see full prescribing information for Hizentra.